| (Values in U.S. Thousands) | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 | Jun, 2016 |
| Sales | -9,999,000 | 1,190 | 760 | 0 | 0 |
| Sales Growth | -840,351.39% | +56.58% | unch | unch | unch |
| Net Income | -9,999,000 | -6,340 | -4,950 | -9,960 | -10,860 |
| Net Income Growth | -157,612.93% | -28.08% | +50.30% | +8.29% | +19.79% |
Cerulean Pharma Cmn (CERU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cerulean Pharma Inc. is a clinical-stage oncology-focused company. The Company manufactures therapeutics in the areas of oncology, cardiovascular, autoimmune, and inflammatory diseases as well as tumor cells. Cerulean Pharma Inc. is based in Cambridge, Massachusetts.